BILLERICA, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed Bart Lagae as its new VP, International Sales & Marketing.
“We are pleased to announce that Bart Lagae has joined our team as VP, International Sales & Marketing. Bart brings a wealth of international experience and significant expertise in building brands, developing and managing sales channels and market expansion,” said Mark Augusti, President and Chief Executive Officer. “I look forward to the contributions Bart will make as a member of Conformis’ team.”
Bart Lagae is an executive with more than 30 years of experience in orthopedic sales management and global marketing, and has a track record of developing and successfully driving product pipeline and business unit growth.
Most recently, Mr. Lagae served as Senior Director, Global Marketing–Knees at Zimmer Biomet, where he worked for 5 years and managed Partial, Primary, and Revision Knee teams and was responsible for product strategy, portfolio, positioning and business pipeline, and led marketing activities for new product introductions. Immediately prior to Zimmer Biomet, Mr. Lagae spent over 10 years at Biomet where he progressed from Sales Representative to Director, Product Management Partial Knees–Global.
Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
In connection with the hiring of Mr. Lagae, Conformis’ Board of Directors granted to Mr. Lagae a restricted stock unit award of 75,000 shares of Conformis’ common stock. The restricted stock unit award is expected to be granted on November 9, 2020 as an inducement material to Mr. Lagae’s acceptance of employment with Conformis in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock unit award vests over four years, with 25% of the total number of shares underlying the award vesting on each one-year anniversary of the grant date, subject to Mr. Lagae’s continued service as an employee of Conformis through the applicable vesting dates.
About Conformis, Inc.
Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers. In clinical studies, the Conformis iTotal CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release about our future expectations, plans and prospects, the anticipated timing of our product launches, and our financial position and results, total revenue, product revenue, gross margin, operations and growth, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these terms or other and similar expressions are intended to identify forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties; risks related to our estimates and expectations regarding our revenue, gross margin, expenses, revenue growth and other results of operations, and the other risks and uncertainties described in the “Risk Factors” sections of our public filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.